Berman Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Berman Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$83K	Buy	765 +246	+47%	+$25.5K	0.01%	500
2021 Q2	$48K	Buy	519 +246	+90%	+$22.6K	0.01%	606
2021 Q1	$24K	Buy	273 +233	+583%	+$19.7K	0.01%	727
2020 Q4	$2K	Buy	40 +15	+60%	+$1.11K	﹤0.01%	1476
2020 Q3	$1K	Hold	25	–	–	﹤0.01%	1570
2020 Q2	$1K	Buy	+25	New	+$1.07K	﹤0.01%	1575

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Berman Capital Advisors's HZNP Position: Q3 2021 in Review

Berman Capital Advisors increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 47% in Q3 2021, buying an estimated $25.5K and bringing the position to 765 shares worth $83K. The position accounts for 0.01% of the portfolio, ranked #500.

Berman Capital Advisors first reported a position in HZNP in Q2 2020 and has held it in 6 quarters since. 572 funds tracked by Wall St. Rank hold HZNP as of Q3 2021.

Berman Capital Advisors held 765 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $83K as of Q3 2021.
Berman Capital Advisors bought 246 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2021, an estimated $25.5K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #500 holding.
Berman Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and has held it in 6 quarters since.
572 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.